Targeted Oncology2m
FDA Grants Fast Track Designation to LBS-007 in AML
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
Targeted Oncology19h
The Clinical Utility of Genetic Risk Scores in Chronic Lymphocytic Leukemia
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
Targeted Oncology22h
Tiragolumab/Atezolizumab Combo Fails to Meet Primary End Point in NSCLC Trial
The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...
Targeted Oncology22h
Novel METTL3 Inhibitor Elicits Clinical Activity Across Tumor Types
STC-15, an investigational RNA methyltransferase inhibitor, has shown promising clinical activity and an encouraging safety ...
Targeted Oncology23h
FDA Receives BLA for RP1 and Nivolumab Combo in Advanced Melanoma
The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...
Targeted Oncology17h
Functional High-Risk is a Leading Rationale for Early CAR T in Myeloma
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...